HOME >> BIOLOGY >> NEWS
Drug breakthrough for psoriasis sufferers

An international team led by a dermatologist at The University of Manchester has found that treatment with the emerging drug infliximab, marketed as Remicade, can quickly and significantly improve psoriasis symptoms.

The European Infliximab for Psoriasis Efficacy and Safety Study (EXPRESS) was a placebo-controlled trial on 378 patients with moderate to severe psoriasis, to test the efficacy and safety of the drug. The findings, published in the 15 October issue of The Lancet, show that 80% of patients achieved at least a 75% improvement in symptoms after ten weeks treatment with the drug, as opposed to just 3% of those receiving a placebo.

Psoriasis is a chronic condition which results when skin cells over-produce and accumulate on the surface of the skin, producing red, scaly 'plaques' which may itch and bleed. It is thought to be genetic in origin and is a consequence of an abnormal inflammatory response in the skin. Around 2% of the population suffer from the disease, with about 30% of cases considered moderate to severe, but until now treatment options have been limited.

Infliximab blocks the activity of 'tumour necrosis factor alpha' (TNF-alpha), a protein involved in inflammation, and the vast majority of the trial subjects treated with the drug achieved clinically-significant levels of skin clearance. Nearly 60% experienced at least a 90% improvement in symptoms or near-complete skin clearance after ten weeks, versus 1% receiving the placebo, whilst 26% achieved complete skin clearance (versus 0% receiving the placebo). The improvements continued throughout the 50-week study.

Professor Christopher Griffiths, the University academic leading the trial from the Dermatology Centre at Hope Hospital, Salford, said: "These results indicate that Infliximab is a very effective therapy among the newer biological treatments for psoriasis. As a dermatologist, I am very encouraged by the data, which show that patients with moderat
'"/>

Contact: Jo Nightingale
jo.nightingale@manchester.ac.uk
4-161-275-8156
University of Manchester
13-Oct-2005


Page: 1 2

Related biology news :

1. 2007 EURYI: 20 young researchers to receive Nobel Prize-sized awards for breakthrough ideas
2. Major breakthrough in understanding how HIV interferes with infected cell division
3. Variant CJD -- Prion amplification breakthrough brings new insights and hopes for a blood test
4. Cloned pigs help scientists towards a breakthrough in Alzheimers
5. Biotech breakthrough could end biodiesels glycerin glut
6. Digestive Disease Week 2007 spotlights breakthrough research in digestive health
7. Stanford scientists make major breakthrough in regenerative medicine
8. Research on grey mold offers possible breakthrough in tomato cultivation
9. Medieval Islamic designs reveal breakthrough in tiled pattern-making
10. Rice breakthrough could prevent multiple fibrotic diseases
11. Sciences breakthrough of the year -- The Poincar Theorem

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/5/2019)... , ... November 05, 2019 , ... ... Dentistry, providing state-of-the-art cosmetic and restorative dentistry to Seattle, WA, including porcelain ... of Dental Surgery degree from the University of Washington, Dr. Kopp is passionate ...
(Date:10/30/2019)... BALTIMORE, Md. (PRWEB) , ... October 30, 2019 ... ... at the 12th Annual CBRNe Convergence in Nashville, TN from Tuesday, November 5, ... and military responses to CBRNe (chemical, biological, radiological, nuclear) and IED (explosive) threats. ...
(Date:10/27/2019)... PETERSBURG, Fla. (PRWEB) , ... October 26, 2019 , ... ... and their unique reseller program. By prioritizing the success of their clients, they’ve earned ... three years in a row, and they’ve won many additional awards and accolades along ...
Breaking Biology News(10 mins):
(Date:11/12/2019)... ... November 12, 2019 , ... ... to educate Americans about the deadly healthcare-associated infection C. diff. The campaign, ... of the epidemic, which kills at least 30,000 people in the U.S. each ...
(Date:11/5/2019)... ... November 04, 2019 , ... Catalent, ... for drugs, biologics, gene therapies, and consumer health products, today announced the ... enhances Catalent’s proven GPEx expression platform through multiple improvements, including utilization of ...
(Date:11/2/2019)... TORONTO (PRWEB) , ... October 31, 2019 , ... ... at Adaptive Biotechnologies in a live webinar on Friday, ... application in immuno-oncology. , Immunosequencing, the science of profiling T-cell receptors (TCRs) ...
(Date:10/29/2019)... (PRWEB) , ... October 28, 2019 , ... CaroGen ... Board: , , Professor Jack R Wands, MD, of Brown ... Wyeth (Pfizer) , Professor Gil Mor, MD, PhD, of Wayne State University, ...
Breaking Biology Technology:
Cached News: